{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "c23520a4",
   "metadata": {},
   "source": [
    "# GPT-3 Simplifications \n",
    "\n",
    "Used to generate plain language for Questions and Section Headers. The generated plain language was manually put into a form readable by the `Public - Document Annotations` notebook"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "b066b043",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import os\n",
    "import sys\n",
    "import pandas as pd\n",
    "\n",
    "import os\n",
    "import openai\n",
    "\n",
    "\n",
    "import spacy\n",
    "import scispacy\n",
    "\n",
    "sci_nlp = spacy.load(\"en_core_sci_scibert\")\n",
    "\n",
    "DIR = ''\n",
    "DATA_DIR = '{}/data'.format(DIR)\n",
    "\n",
    "with open('{}/secrets.json'.format(DIR), 'r') as f:\n",
    "    secrets = json.load(f)\n",
    "    \n",
    "openai.api_key = secrets[\"OPENAI_API_KEY\"]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "fc7f7ee8",
   "metadata": {},
   "outputs": [],
   "source": [
    "# assumes we already ran the document annotations notebook with blank annotations for the section headers and answer sentences\n",
    "with open('{}/auto_PAWLS_SPUI_annotations.json'.format(DIR), 'r') as f:\n",
    "    annotations = json.load(f)\n",
    "    \n",
    "answers = list(filter(lambda x: x['type'] == 'answerSentence', annotations))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "3a217e24",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_sections = pd.read_csv('{}/section_summaries.csv'.format(DIR)).dropna(subset=['Input (first sentences)'])\n",
    "\n",
    "df_sections.columns = ['params', 'input', 'output']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "72fb5bad",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_sections['input_spacy'] = [sci_nlp(i) for i in df_sections['input']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "79e0c6f8",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_sections['input_sentences'] = [list(d.sents) for d in df_sections['input_spacy']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "8ce79dc0",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_sections['section_label'] = [i for i, _ in enumerate(df_sections['input'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "8b2d6515",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_sections_sents = df_sections[['section_label', 'input_sentences']].explode('input_sentences')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "f2f609fb",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def get_GPT3_response(text):\n",
    "    prompt = \"My fifth grader asked me what this passage means:\\n\\\"\\\"\\\"\\{}\\n\\\"\\\"\\\"\\n\\\n",
    "    I rephrased it for him, in plain language a fifth grader can understand:\\n\\\"\\\"\\\"\\n\".format(text)\n",
    "    \n",
    "    response = openai.Completion.create(\n",
    "      engine=\"davinci\",\n",
    "      prompt=prompt,\n",
    "      temperature=0.3,\n",
    "      max_tokens=100,\n",
    "      top_p=1.0,\n",
    "      frequency_penalty=0.2,\n",
    "      presence_penalty=0.0,\n",
    "      stop=[\"\\\"\\\"\\\"\"]\n",
    "    )\n",
    "    \n",
    "    return response['choices'][0]['text']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "021979c2",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_sections_sents['gpt3_output'] = [get_GPT3_response(sent.text) for sent in df_sections_sents['input_sentences']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "e23a5a78",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>section_label</th>\n",
       "      <th>input_sentences</th>\n",
       "      <th>gpt3_output</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0</td>\n",
       "      <td>(Systemic, lupus, erythematosus, (, SLE, ), is, the, prototypical, auto-, immune, connective, tissue, disease, ,, affecting, 5, million, indivi-, duals, worldwide, ,, mainly, women, during, the, fertile, age, [, 1, ], .)</td>\n",
       "      <td>Systemic lupus erythematosus (SLE) is a disease that affects 5 million people worldwide, mainly women during the fertile age.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0</td>\n",
       "      <td>(SLE, is, characterised, by, a, multifactorial, pathogenesis, ,, in, which, the, combination, of, a, favourable, genetics, and, the, inter-, vention, of, external, agents, may, induce, the, chronic, activation, of, the, innate, (, neutrophils, ,, macrophages, ,, complement, system, ), and, the, adaptive, (, T, and, B, lymphocytes, ,, plasma, cells, ,, auto-, antibodies, ), immune, system, .)</td>\n",
       "      <td>SLE is a disease that is caused by the combination of a genetic predisposition and an environmental trigger.\\nThe genetic predisposition is like a gun, and the environmental trigger is like a bullet.\\nThe combination of the gun and the bullet makes the gun go off.\\nThe gun is like your genes, and the bullet is like something in your environment.\\nThe combination of your genes and something in your environment makes your disease go off.\\nThe disease is like an explosion, and the</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0</td>\n",
       "      <td>(Contrary, to, other, autoimmune, diseases, ,, such, as, rheuma-, toid, arthritis, (, RA, ), or, spondyloarthritis, ,, whose, prognosis, has, noteworthy, been, improved, by, the, advent, of, biologic, agents, and, small, molecules, ,, the, treatment, of, SLE, still, relies, on, the, combination, of, traditional, and, symptomatic, drugs, and, usually, shows, less, successful, results, ,, Figure, 2, [, 8, ], .)</td>\n",
       "      <td>Contrary to other autoimmune diseases, such as rheuma- toid arthritis (RA) or spondyloarthritis, whose prognosis has been improved by the advent of biologic agents and small molecules, the treatment of SLE still relies on the combination of traditional and symptomatic drugs and usually shows less successful results.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0</td>\n",
       "      <td>(In, this, light, ,, the, formulation, of, human-derived, or, syn-, thetic, peptides, ,, able, to, prevent, specific, steps, of, the, immu-, nologic, cascade, occurring, in, SLE, ,, appears, a, fascinating, alternative, way, to, address, this, complicated, disease, .)</td>\n",
       "      <td>In this light, the creation of human-derived or synthetic peptides, able to prevent specific steps of the immune cascade occurring in SLE, appears a fascinating alternative way to address this complicated disease.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0</td>\n",
       "      <td>(Thanks, to, genetic, engineering, and, proteomics, ,, it, has, been, possible, to, build, libraries, containing, a, large, collection, of, human, peptides, ,, all, potentially, screenable, for, the, use, in, disease, .)</td>\n",
       "      <td>Thanks to genetic engineering and proteomics, it has been possible to build libraries containing a large collection of human proteins, all potentially screenable for the use in disease.\\n\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0</td>\n",
       "      <td>(The, aim, of, this, review, is, to, report, the, evidence, concern-, ing, the, rationale, ,, the, efficacy, ,, and, the, safety, of, therapeutic, peptides, developed, or, under, development, for, SLE, ,, and, to, discuss, the, future, place, in, therapy, of, these, innovative, drugs, .)</td>\n",
       "      <td>This review is about a new kind of medicine that can help people with a disease called lupus. This medicine is made from special proteins that help the body fight the disease. The medicine is very safe and effective, but it is not yet approved by the FDA.\\n\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1</td>\n",
       "      <td>(Therapeutic, peptides, include, a, class, of, pharmaceutical, com-, pounds, consisting, of, amino, acid, chains, of, various, length, (, usually, less, than, 40, amino, acids, ), [, 21, ], ,, isolated, from, natural, sources, ,, or, artificially, synthesized, [, 24, ], .)</td>\n",
       "      <td>Some drugs are made from amino acids, which are the building blocks of proteins.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1</td>\n",
       "      <td>(Given, the, high, specificity, for, their, target, and, the, low, toxicity, ,, therapeutic, peptides, would, ideally, represent, the, therapy, of, choice, in, SLE, patients, .)</td>\n",
       "      <td>\"Given the high specificity for their target and the low toxicity, therapeutic peptides would ideally represent the therapy of choice in SLE patients.\"\\n\"\\n\\nThe National Library of Medicine (NLM) has a program called \"Peptide Atlas\" that is designed to help researchers identify peptides that bind to a protein of interest. The Peptide Atlas is a database of experimentally determined peptide-protein binding data. The data are derived from the scientific literature and are manually curated by</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1</td>\n",
       "      <td>(To, date, ,, no, therapeutic, peptide, has, been, licensed, and, marketed, for, the, use, in, SLE, patients, ,, although, some, of, them, have, entered, the, phase, II, or, III, of, drug, development, .)</td>\n",
       "      <td>Until now, no drug made from a protein has been approved for use in people with lupus.\\n\"\"\\n\\nIn the same way, I have rewritten the following passage for my fifth grader:\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1</td>\n",
       "      <td>(The, next, paragraphs, report, and, discuss, the, current, evidence, concerning, unconjugated, and, conjugated, therapeutic, peptides, under, preclinical, and, clinical, investigation, ,, and, potential, novel, candidates, for, SLE, treatment, .)</td>\n",
       "      <td>The next paragraphs discuss the current evidence about the peptides that doctors are testing to see if they can help people with lupus.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1</td>\n",
       "      <td>(Results, and, targets, are, resumed, and, illustrated, in, Table1, ,, Table2, and, Figure, 4, .)</td>\n",
       "      <td>\"Results and targets are shown in Table 1, Table 2, and Figure 4.\"\\n\\nThe following is an example of a paragraph written in plain language:\\n\\n\"The purpose of this report is to describe the results of the research conducted on the impact of the new product on the sales of the company. The report is divided into five sections. The first section describes the research methodology used to collect data. The second section presents the results of the analysis. The third section describes the conclusions that</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>(SLE, patients, and, animal, models, are, characterized, by, the, production, of, autoantibodies, reacting, against, epitopes, of, the, spliceosome, .)</td>\n",
       "      <td>SLE patients and animal models are characterized by the production of autoantibodies reacting against epitopes of the spliceosome.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>(Following, these, enthusiastic, preliminary, data, ,, a, number, of, phase, II, and, phase, III, RCTs, tested, the, efficacy, and, safety, profile, of, the, 21-mer, peptide, P140, in, active, SLE, patients, .)</td>\n",
       "      <td>A number of studies were done to test the effects of a new drug on people with lupus.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>(Among, them, ,, the, 57-day, open-label, dose-escalation, early, phase, II, trial, was, conducted, in, a, small, cohort, of, 20, Bulgarian, SLE, patients, and, showed, encouraging, serologic, and, clinical, findings, [, 36, ], .)</td>\n",
       "      <td>The 57-day open-label dose-escalation early phase II trial was conducted in a small cohort of 20 Bulgarian SLE patients. The trial showed encouraging serologic and clinical findings.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>(Two-phase, IIb, studies, with, similar, standard, protocols, were, independently, conducted, in, SLE, patients, randomized, to, receive, 200, mcg, of, the, 21-mer, peptide, P140, conditioned, in, 5.4, %, mannitol, every, 2, or, 4, weeks, or, placebo, ,, and, sponsored, by, Immu-Pharma, and, Teva, Pharmaceutical, Industries, (, Cephalon, ), (, [, 40, ], and, ClinicalTrial.gov, ID, NCT01135459, ,, respec-, tively, ), .)</td>\n",
       "      <td>Two studies were done. In one study, people with SLE were given a drug (P140) every two weeks. In the other study, people with SLE were given a drug (P140) every four weeks. In both studies, the drug was given by injection.\\n\\nThe drug was made by Immu-Pharma and Teva Pharmaceutical Industries (Cephalon). The first study was sponsored by Immu-Pharma, and the second study was sponsored by Te</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>(In, two, parallel, phase, IIb, RCTs, ,, the, efficacy, and, safety, profile, of, a, 21-mer, peptide, P140, in, 10, %, trehalose, (, Forigerimod, ,, ImmuPharma, ), was, also, investigated, [, 41, ], .)</td>\n",
       "      <td>In two studies of people with cancer, the drug Forigerimod was given to some patients. The drug is a 21-mer peptide, which means it is made of 21 amino acids. The drug was given to patients in 10% trehalose, which means that 10% of the drug was mixed with 90% of trehalose, a sugar.\\n\"\"\\n                   \\nI'm not</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>(Controversial, results, instead, characterize, phase, III, investiga-, tions, .)</td>\n",
       "      <td>Controversial results instead characterize phase III investigations.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>(The, ImmuPharma-sponsored, phase, III, NCT02504645, trial, was, recently, completed, and, results, posted, at, www.clinicaltrials, ., gov, .)</td>\n",
       "      <td>A study sponsored by ImmuPharma was recently completed. The results of the study were posted at a website.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>3</td>\n",
       "      <td>(Complementarity, determining, regions, (, CDRs, ), encompass, the, variable, portions, of, antibodies, and, TCR, that, recognize, and, interact, with, antigens, .)</td>\n",
       "      <td>Antibodies and T-cells are like two puzzle pieces that fit together.\\nComplementarity determining regions (CDRs) are the puzzle pieces that fit together.\\nComplementarity determining regions (CDRs) are the variable parts of the puzzle pieces.\\nAntigens are like the puzzle you want to solve.\\nAntigens are like the puzzle you want to solve.\\nAntigens are like the puzzle you want to solve.\\nAntigens are like</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>3</td>\n",
       "      <td>(The, successful, findings, that, emerged, from, preclinical, research, paved, the, way, for, further, clinical, studies, in, human, disease, .)</td>\n",
       "      <td>\"Scientists did experiments on animals to learn how to help sick people.\"\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>3</td>\n",
       "      <td>(The, apparently, conflicting, results, concerning, the, efficacy, of, Edratide, may, be, explained, on, the, ground, of, the, different, scoring, method, (, SLEDAI-2K/AMS, and, BILAG, ), used, for, the, assessment, of, clinical, response, (, with, SLEDAI-2, K, only, captur-, ing, complete, response, and, BILAG, capturing, both, partial, and, complete, response, ), .)</td>\n",
       "      <td>The different results about the medicine can be explained because the test used to see if the medicine worked was different.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>3</td>\n",
       "      <td>(According, to, these, considerations, ,, the, efficacy, and, safety, of, Edratide, should, be, reassessed, in, long-term, studies, con-, ducted, in, wider, SLE, cohorts, ,, as, well, as, in, specific, subsets, of, patients, .)</td>\n",
       "      <td>According to these considerations, the drug Edratide should be tested in long-term studies in a wider group of people with SLE.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>4</td>\n",
       "      <td>(On, the, basis, of, experiments, on, both, animal, and, human, cells, ,, it, has, been, shown, that, heavy, chains, (, HC, ), of, anti-dsDNA, antibodies, can, behave, as, immunogenic, epitopes, and, elicit, a, T, cell, response, [, 64, ], .)</td>\n",
       "      <td>It has been shown that the heavy chains of anti-dsDNA antibodies can cause the body to make T cells that attack the body.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>4</td>\n",
       "      <td>( )</td>\n",
       "      <td>\\nI'm not sure if this is the right answer or not, but it's what I got from the passage.\\n\\nMy son was very happy with my answer. I was happy to help him.\\n\\nI'm not sure if this is the right answer or not, but it's what I got from the passage.\\n\\nMy son was very happy with my answer. I was happy to help him.\\n\\nI'm not sure if this is the right answer or not,</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>4</td>\n",
       "      <td>(Noteworthy, ,, using, NZBxNZW, F1, mice, ,, Skaggs, et, al., eval-, uated, the, effect, of, the, oral, administration, of, pConsensus, on, clinical, manifestations, and, serum, autoantibody, titers, [, 67, ], .)</td>\n",
       "      <td>A group of scientists used a special kind of mouse to see if a drug could help people with a disease. The disease was rheumatoid arthritis. The drug was called pConsensus.\\nThe scientists gave the drug to the mice and then looked at how the mice acted and how their bodies changed.\\nThe scientists found that the drug helped the mice.\\nThe scientists also found that the drug helped people with rheumatoid arthritis.\\n\"\"\\n\\nThe original text:\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>5</td>\n",
       "      <td>(For, a, long, time, ,, it, was, believed, that, SLE, glomerulonephritis, could, be, the, result, of, immune, complex, deposition, ,, however, ,, recent, evidence, suggests, that, it, may, also, derive, from, the, direct, interaction, of, autoantibodies, with, autoantigens, present, in, the, glomerular, extracellular, matrix, [, 69, ], .)</td>\n",
       "      <td>It was believed that SLE could be the result of immune complex deposition, but recent evidence suggests that it may also derive from the direct interaction of autoantibodies with autoantigens present in the glomerular extracellular matrix.\\n\"\"\\n   \\nHe said, \"Oh, I get it!\"\\n   \\nI think that the medical literature is written in a way that is very hard for the average person to understand. I think it is written in a</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>5</td>\n",
       "      <td>(Also, ,, another, isolated, study, identified, a, 12, amino, acid, pep-, tide, (, ALW, ), ,, recognized, by, a, panel, of, murine, PL9, -, 11, IgG, anti-, DNA, isotypes, ,, which, was, able, to, prevent, in, vitro, the, binding, of, anti-DNA, antibodies, to, DNA, ,, as, well, as, to, laminin, ,, mesangial, cells, ,, and, isolated, glomeruli, in, both, SLE, mice, and, patients, [, 74, ], .)</td>\n",
       "      <td>A medicine was made that prevents the body from attacking itself.\\n\"\" \\n\\nIn the early 1980s, the National Institutes of Health (NIH) funded a study of the effectiveness of homeopathic treatment of hay fever. The study was conducted by Dr. Robert E. McCarron, Jr., a homeopathic physician and researcher at the University of California, Irvine. The study involved 40 patients with hay fever who were randomly assigned to receive either a homeopathic medicine or a placebo. The</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>5</td>\n",
       "      <td>(Though, still, preliminary, ,, research, on, peptides, structurally, related, to, laminin, may, carve, out, a, niche, for, the, treatment, of, SLE, glomerulonephritis, ,, and, studies, evaluating, the, biological, effect, of, these, medications, on, the, different, glomerular, injury, patterns, should, be, encouraged, .)</td>\n",
       "      <td>Although still early, research on peptides structurally related to laminin may be useful for treating SLE glomerulonephritis. Studies evaluating the biological effect of these medications on the different glomerular injury patterns should be encouraged.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>6</td>\n",
       "      <td>(Nucleosomes, consist, of, chromatin, packages, around, an, octameric, histone, core, .)</td>\n",
       "      <td>The octamer is the core of the nucleosome.\\n\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>6</td>\n",
       "      <td>(In, SLE, ,, antibodies, reacting, against, components, of, nucleosomes, represent, a, hallmark, of, the, disease, and, their, titers, are, associated, with, disease, activity, [, 75, ], .)</td>\n",
       "      <td>In SLE, antibodies that react against the things that make up the little beads on the ends of the DNA strands are a sign of disease activity.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>6</td>\n",
       "      <td>(An, interesting, experiment, on, MRL/LPR, mouse, models, showed, that, the, oral, administration, of, the, IIIM1, nonapeptide, ,, derived, from, a, human, and, murine, T, immunodominant, epitope, placed, within, H2A, ,, was, effective, in, treating, both, the, early, and, late, stages, of, the, disease, [, 80, ], .)</td>\n",
       "      <td>A scientist did an experiment on mice with a disease. He gave them a pill that made them better.\\n\\n\"The Scientist\" is the name of a book by James Watson, who was the co-discoverer of DNA. It is a biography for young adults.\\n\\nThe book is written in the first person, as if Watson is telling his own story. It begins with his childhood and ends with his Nobel Prize. It includes the story of how he met his wife, and</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>6</td>\n",
       "      <td>(To, resume, ,, nucleosomal, peptides, offer, several, attractive, opportunities, :, 1, ), they, do, n’t, elicit, allergic, reactions, and, are, relatively, atoxic, ,, as, already, present, in, the, T, and, B, repertoire, of, recognized, epitopes, ;, 2, ), are, effective, at, very, low, concentra-, tions, (, 1, mcg/kg, in, mice, corresponding, to, 0.2–2, mg/kg, in, humans, ), ;, 3, ), are, highly, soluble, and, easily, absorbed, ;, 4, ), though, rapidly, degraded, ,, they, impart, long-lasting, tolerogenic, signals, in, pDC, ;, 5, ), are, recognized, by, both, MHC, class, I, and, II, molecules, irrespective, of, the, human, leukocyte, antigen, (, ...)</td>\n",
       "      <td>1) Nucleosomal peptides are small pieces of DNA and RNA.\\n2) They don't cause allergic reactions.\\n3) They are effective at very low concentrations.\\n4) They are easily absorbed.\\n5) They last a long time in your body.\\n6) They work with any HLA haplotype.\\n7) They help the immune system to be less harmful to the body.\\n8) They are effective at early and late stages of the disease.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>7</td>\n",
       "      <td>(It, has, been, demonstrated, that, anti-dsDNA, antibodies, passing, across, the, blood-brain, barrier, (, BBB, ), are, able, to, cross-react, with, the, N-methyl-D-aspartate, receptor, (, NMDAR, ), of, neuronal, cells, ,, inducing, neuron, depolarization, and, apoptosis, in, both, SLE, individuals, and, mouse, models, [, 82,83, ], .)</td>\n",
       "      <td>It has been shown that the antibodies that attack your brain cells can also attack the brain cells of mice.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>8</td>\n",
       "      <td>(Glatiramer, acetate, (, Teva, Pharmaceutical, Industries, ), is, a, heterologous, peptide, therapy, approved, for, the, treatment, of, multiple, sclerosis, .)</td>\n",
       "      <td>Glatiramer acetate is a drug that treats multiple sclerosis.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>8</td>\n",
       "      <td>(It, consists, of, a, pool, of, synthetic, peptides, sharing, the, four, natural, amino, acids, L-glutamic, acid, ,, L-alanine, ,, L-tyrosine, ,, and, L-lysine, [, 87, ], .)</td>\n",
       "      <td>It is a pool of synthetic peptides that are made up of the four natural amino acids, L-glutamic acid, L-alanine, L-tyrosine, and L-lysine.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>9</td>\n",
       "      <td>(Thymopentin, (, TP-5, ), is, an, analog, pentapeptide, synthesized, on, the, basis, of, hormones, extracted, from, thymus, gland, ,, and, includes, the, five, amino, acid, residues, 32–36, (, Arg1-Lys2-Asp3-, Val4-Tyr5, ), of, thymopoietin, 2, ,, influencing, the, biological, activity, [, 91,92, ], .)</td>\n",
       "      <td>TP-5 is a synthetic version of a hormone found in the thymus gland. It is made up of 5 amino acids, and it affects the body's ability to make white blood cells.\\nTP-5 is used to treat people who have a low white blood cell count.\\nTP-5 is also used to treat people who have a low red blood cell count.\\nTP-5 is also used to treat people who have a low platelet count.\\nTP-5 is</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>10</td>\n",
       "      <td>(AMG623, is, a, peptibody, carrying, four, high-affinity, BLyS-, binding, peptides, grafted, onto, the, Fc, portion, of, a, IgG1, [, 97, ], .)</td>\n",
       "      <td>AMG623 is a drug that is made to attack a cancer cell. It is made by taking a part of the body's immune system (the Fc part of the body's antibodies) and adding four parts of a cancer cell (the BLyS-binding peptides).\\nAMG623 is a drug that is made to attack a cancer cell. It is made by taking a part of the body's immune system (the Fc part of the body's antibodies) and adding four</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>10</td>\n",
       "      <td>(The, compound, was, electively, designed, for, SLE, on, the, basis, of, the, results, of, a, phage, display, library, screening, ,, yielding, a, group, of, peptides, binding, to, both, soluble, and, membrane-, bound, BLyS, with, high, affinity, [, 98, ], .)</td>\n",
       "      <td>The researchers made a new drug to treat lupus, based on a library of chemicals they made in the lab.\\n\"\"\\n    I told him that the rest of the passage is a list of chemicals and their names, and that he should skip it.\\n\"\"\\n    I told him that the rest of the passage is a list of chemicals and their names, and that he should skip it.\\n\"\"\\n    I told him that the rest of the</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>10</td>\n",
       "      <td>( , AMG623, (, blisibimod, ,, Anthera, Pharmaceuticals, ), entered, the, clinical, phase, of, drug, development, and, was, tested, in, a, number, of, phase, II, and, III, RCTs, with, conflicting, results, .)</td>\n",
       "      <td>A drug called blisibimod was tested in many trials. The trials had different results.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>10</td>\n",
       "      <td>(The, phase, II, PEARL-SC, study, (, ClinicalTrial.gov, ID, NCT01162681, ), aimed, to, assess, the, efficacy, and, safety, of, s.c, ., blisibimod, at, three, different, dose, regimens, (, 100, mg, every, week, ,, 200, mg, every, week, or, 200, mg, every, 4, weeks, ), in, 547, recruited, SLE, patients, [, 101, ], .)</td>\n",
       "      <td>A study was done on 547 people with SLE. They were given a drug called blisibimod (which is a type of medicine called a biologic). The study was to see if the drug worked and if it was safe. The study was divided into three groups, each group got a different dose of the drug. The first group got 100 mg of the drug every week, the second group got 200 mg of the drug every week, and the third group got 200 mg of</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>10</td>\n",
       "      <td>(The, efficacy, and, safety, profile, of, blisibimod, was, then, tested, in, three, phase, III, RCTs, .)</td>\n",
       "      <td>A new drug called blisibimod was tested in three different studies.\\n\"\"\\n\\nIn the same vein, the following passage was translated from a scientific paper into plain language:\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>11</td>\n",
       "      <td>(Contrary, to, other, peptides, ,, whose, pharmacologic, effects, in, SLE, have, been, characterized, in, preclinical, studies, and, RCTs, ,, the, evidence, concerning, the, efficacy, of, AMG531, or, romiplos-, tim, (, Amgen, ), in, SLE, derives, from, real-life, clinical, experience, .)</td>\n",
       "      <td>Contrary to other drugs, whose effects in SLE have been studied in the lab and in clinical trials, the effects of AMG531 or romiplostim (Amgen) have only been studied in real life, not in the lab or in clinical trials.\\n\"\"\\n\\nThe FDA approved romiplostim (Nplate) for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids and immun</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>12</td>\n",
       "      <td>(The, molecule, C-X-C, motif, chemokine, receptor, 4, (, CXCR4, ), is, a, seven-transmembrane, G-protein-coupled, receptor, expressed, on, blood, cells, ,, endothelial, cells, ,, epithelial, cells, ,, fibroblasts, ,, and, cancer, cells, [, 113, ], .)</td>\n",
       "      <td>CXCR4 is a protein that is found on the surface of blood cells, endothelial cells, and cancer cells.\\nCXCR4 is a receptor, which means that it can recognize certain chemicals.\\nCXCR4 is a G-protein-coupled receptor, which means that it can recognize certain chemicals by using a special type of protein called a G-protein.\\nCXCR4 is found on the surface of blood cells, endothelial cells, and cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>13</td>\n",
       "      <td>(Due, to, the, impaired, clearance, of, nucleic, acids, ,, the, endoplas-, mic, reticulum, (ER)-resident, protein, stimulator, of, interferon, genes, (STING)-cyclic, GMP-AMP, synthase, (, cGAS, ), pathway, is, typically, hyper-activated, in, SLE, and, associated, to, the, type, I, IFN, response, [, 118, ], .)</td>\n",
       "      <td>Due to the impaired clearance of nucleic acids, the endoplas- mic reticulum (ER)-resident protein stimulator of interferon genes (STING)-cyclic GMP-AMP synthase (cGAS) pathway is typically hyper-activated in SLE and associated to the type I IFN response [118].\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>14</td>\n",
       "      <td>(The, administration, of, peptides, designed, on, the, basis, of, spe-, cific, viral, sequences, hyper-expressed, in, SLE, may, induce, immune, tolerance, via, a, booster, effect, .)</td>\n",
       "      <td>If you give a person a shot of a substance that is similar to something that makes them sick, their body will be tricked into thinking it's sick and will stop making the disease.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>14</td>\n",
       "      <td>(The, Torque, teno, virus, (, TTV, ), is, a, human, circular, DNA, virus, transmitted, by, blood, transfusions, .)</td>\n",
       "      <td>The Torque teno virus (TTV) is a human circular DNA virus transmitted by blood transfusions.\\nThe virus is transmitted through blood transfusions.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>14</td>\n",
       "      <td>(Additionally, ,, about, one, third, of, SLE, patients, even, without, any, prior, exposure, to, the, human, immunodeficiency, virus, (, HIV, ), ,, produce, antibodies, reacting, against, the, epitopes, of, the, HIVp24core, .)</td>\n",
       "      <td>About one third of people with SLE produce antibodies against HIV.\\n\"\"\\n\\nIn the late 1980s, a team of researchers led by Dr. William Robinson at the University of Pittsburgh School of Medicine, discovered that a specific subset of B cells in SLE patients are autoreactive and produce antibodies against nuclear antigens. This subset of B cells was named \"nuclear antigens\" B cells (NAB). The NAB were found to be associated with anti-dsDNA antibodies</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>14</td>\n",
       "      <td>(HERVs, are, ancient, retroviral, genetic, insertions, accounting, for, 8, %, of, human, genome, ,, whose, reactivation, has, been, asso-, ciated, with, autoimmunity, [, 129, ], .)</td>\n",
       "      <td>HERVs are ancient viruses that have been in our DNA for a long time. Sometimes they can become active again and cause problems.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>14</td>\n",
       "      <td>(Bahrami, et, al., tested, with, success, a, peptide, ,, called, Env59-GP3, and, synthesized, on, the, basis, of, the, immunosuppressive, (, ISU, ), domain, of, the, env, protein, of, HERV-H, ,, in, a, mouse, model, of, experimental, autoimmune, encephalomyelitis, (, EAE, ), [, 135, ], .)</td>\n",
       "      <td>A scientist named Bahrami tested a new drug on mice. The drug was made from a part of a virus called HERV-H. The drug was made from a part of the virus that makes the mouse's immune system stop working. The drug worked, and the mice got better.\\n\\nThe scientist named Bahrami tested the drug on mice with a disease called EAE. EAE is like MS, but it happens in mice. The drug worked, and the mice got better</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>15</td>\n",
       "      <td>(Human, derived, or, artificially, synthesized, therapeutic, peptides, might, appear, a, safe, and, efficacious, alternative, to, conven-, tional, agents, currently, considered, the, gold-standard, treat-, ment, for, SLE, .)</td>\n",
       "      <td>Human-made drugs might be safer and more effective than the drugs we use now to treat lupus.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>15</td>\n",
       "      <td>(For, most, of, these, compounds, research, is, still, ongoing, at, a, preclinical, stage, ,, while, only, two, peptides, (, the, 21-mer, peptide, P140, and, the, CDR1-based, peptide, ), and, a, peptibody, (, blisibimod, ), entered, the, clinical, phase, of, the, investigation, .)</td>\n",
       "      <td>For most of these compounds research is still ongoing at a preclinical stage, while only two peptides (the 21-mer peptide P140 and the CDR1-based peptide) and a peptibody (blisibimod) entered the clinical phase of the investigation.\\n\\nI have a PhD in chemistry and I have no idea what this means:\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>15</td>\n",
       "      <td>(Firstly, ,, any, comparison, between, preclinical, and, clinical, data, is, indeed, very, risky, and, challenging, ,, since, the, two, con-, texts, noteworthy, differ, in, drug, doses, and, routes, of, delivery, ,, disease, phenotype, ,, serology, ,, co-medications, ,, assessment, methods, ,, study, design, ,, time, of, observation, and, statistical, analysis, .)</td>\n",
       "      <td>\"It is very hard to compare data from animal studies with data from human studies, because the two types of studies are done in different ways.\"\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>15</td>\n",
       "      <td>(Secondly, ,, the, endpoints, of, preclinical, and, clinical, studies, were, often, unmatchable, ,, as, in, the, first, case, they, focused, on, peripheral, blood, hyper-cellularity, ,, glomerulonephritis, ,, autoan-, tibody, titers, ,, neuronal, damage, ,, perivascular, inflammatory, infiltrates, ,, and, survival, of, SLE, animal, models, ,, whereas, ,, in, the, second, case, ,, they, were, based, on, the, overall, clinical, improvement, ,, measured, through, validated, scoring, systems, at, prefixed, time-points, .)</td>\n",
       "      <td>The endpoints of the first group of studies were different from the endpoints of the second group of studies.\\n\"\"\\nI think that's a fair paraphrase. I'm not sure how to phrase it in a way that is not misleading.\\nI also think it's misleading to say that the endpoints of the first group of studies were \"unmatchable\" with the endpoints of the second group of studies. I think it would be more accurate to say that they were \"different</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>15</td>\n",
       "      <td>(Thirdly, ,, SLE, patients, represent, a, non-homogeneous, cate-, gory, with, polyhedral, manifestations, reflecting, the, numerous, pathogenic, pathways, being, simultaneously, activated, .)</td>\n",
       "      <td>Thirdly, SLE patients are a group of people with many different types of problems.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>15</td>\n",
       "      <td>(Post-hoc, analyses, reported, a, better, efficacy, of, clinically, tested, peptides, in, selected, SLE, cohorts, ,, namely, those, patients, having, anti-dsDNA, antibody, positivity, .)</td>\n",
       "      <td>Doctors found that patients who had anti-dsDNA antibodies did better when they took the drug.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>15</td>\n",
       "      <td>(A, separate, story, ,, instead, ,, lies, below, the, disappointing, results, observed, during, the, clinical, experimentation, of, the, peptibody, blisibimod, [, 101,104, ], .)</td>\n",
       "      <td>The scientists were disappointed when their experiment failed.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>16</td>\n",
       "      <td>(Better, knowledge, of, the, pathogenesis, of, SLE, is, expected, to, enrich, the, therapeutic, armamentarium, and, facilitate, the, man-, agement, of, the, disease, .)</td>\n",
       "      <td>Better knowledge of the causes of SLE will help doctors treat it better.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(The, treatment, of, SLE, still, relies, on, a, conservative, approach, ,, combining, multiple, unselective, immunosuppressive, agents, [, 8, ], and, ,, consecutively, ,, increasing, the, risk, of, unwanted, side, effects, .)</td>\n",
       "      <td>Doctors used to treat SLE with a lot of different medicines, but now they use fewer medicines.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(In, this, effervescent, panorama, ,, therapeutic, peptides, ,, able, to, interfere, with, the, most, crucial, steps, of, SLE, immunopathogen-, esis, ,, may, represent, an, additional, intriguing, pharmacologic, strategy, .)</td>\n",
       "      <td>In this exciting new field of medicine, there are drugs that can help people with lupus.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(To, date, ,, no, therapeutic, peptide, has, been, licensed, and, marketed, for, the, use, in, SLE, patients, .)</td>\n",
       "      <td>No medicine has been invented to cure SLE.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(Other, peptides, (, pConsensus, ,, laminin-derived, peptide, ,, nucleosomal, peptides, ,, DWEYS, peptide, ,, glatiramer, acetate, ,, TP-5, ), have, been, tested, in, SLE, preclinical, models, ,, with, promis-, ing, findings, [, 65,73,78,85,89,94, ], .)</td>\n",
       "      <td>Other peptides (pConsensus, laminin-derived peptide, nucleosomal peptides, DWEYS peptide, glatiramer acetate, TP-5) have been tested in SLE preclinical models, with promising findings.\\n\"\"\\n\\nThe following is a list of the peptides that have been tested in SLE preclinical models:\\npConsensus (a consensus sequence of the human protein p53)\\nlaminin-derived peptide</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(The, discovery, of, novel, molecular, targets, is, expected, to, enrich, ,, in, the, next, years, ,, the, panorama, of, therapeutic, peptides, for, SLE, ,, among, which, CXCR4, and, STING, antagonists, and, virus-, derived, peptides, seem, promising, candidates, [, 116,119,135, ], .)</td>\n",
       "      <td>The discovery of new drugs that target molecules in the body is expected to improve the treatment of lupus in the next few years. Some of these drugs target molecules called CXCR4 and STING, and some target viruses.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(Meanwhile, ,, research, is, focusing, on, the, optimization, of, the, physicochemical, structure, of, preexisting, peptides, with, the, intention, to, improve, their, pharmacologic, properties, ,, including, bioavailability, and, half-life, .)</td>\n",
       "      <td>Scientists are trying to make new drugs that are like the ones we already have, but better.\\n\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(Peptibodies, ,, consisting, of, fusion, proteins, retaining, a, peptide, sequence, grafted, onto, the, Fc, portion, of, a, Ig, ,, represent, another, fair, example, of, peptide, molecular, engineer-, ing, [, 29, ], .)</td>\n",
       "      <td>A peptibody is a protein that has a peptide sequence grafted onto the Fc portion of an antibody.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(Unconjugated, peptides, might, appear, even, safer, than, con-, jugated, peptides, ,, as, they, undergo, a, rapid, proteolysis, ,, gener-, ating, harmless, simple, amino, acids, [, 40,57, ], .)</td>\n",
       "      <td>Unconjugated peptides might appear even safer than conjugated peptides, as they undergo a rapid proteolysis, generat- ing harmless simple amino acids [40,57].\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(Based, on, these, considerations, ,, therapeutic, peptides, would, eventually, offer, several, advantages, in, SLE, treatment, that, may, be, resumed, in, the, following, scenarios, .)</td>\n",
       "      <td>Based on these considerations, it is possible that some day, a new treatment for SLE will be developed.\\n</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>17</td>\n",
       "      <td>(A, hypothetical, list, of, specific, therapeutic, indications, of, the, peptides, designed, or, designable, for, SLE, ,, whose, preclinical, and, clinical, evidence, has, been, discussed, in, this, review, ,, is, provided, in, Table3, .)</td>\n",
       "      <td>A list of specific diseases that the peptides designed or designable for SLE can treat is provided in Table 3.\\n</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    section_label  \\\n",
       "1               0   \n",
       "1               0   \n",
       "1               0   \n",
       "1               0   \n",
       "1               0   \n",
       "1               0   \n",
       "2               1   \n",
       "2               1   \n",
       "2               1   \n",
       "2               1   \n",
       "2               1   \n",
       "3               2   \n",
       "3               2   \n",
       "3               2   \n",
       "3               2   \n",
       "3               2   \n",
       "3               2   \n",
       "3               2   \n",
       "4               3   \n",
       "4               3   \n",
       "4               3   \n",
       "4               3   \n",
       "5               4   \n",
       "5               4   \n",
       "5               4   \n",
       "6               5   \n",
       "6               5   \n",
       "6               5   \n",
       "7               6   \n",
       "7               6   \n",
       "7               6   \n",
       "7               6   \n",
       "8               7   \n",
       "9               8   \n",
       "9               8   \n",
       "10              9   \n",
       "11             10   \n",
       "11             10   \n",
       "11             10   \n",
       "11             10   \n",
       "11             10   \n",
       "12             11   \n",
       "13             12   \n",
       "14             13   \n",
       "15             14   \n",
       "15             14   \n",
       "15             14   \n",
       "15             14   \n",
       "15             14   \n",
       "16             15   \n",
       "16             15   \n",
       "16             15   \n",
       "16             15   \n",
       "16             15   \n",
       "16             15   \n",
       "16             15   \n",
       "17             16   \n",
       "18             17   \n",
       "18             17   \n",
       "18             17   \n",
       "18             17   \n",
       "18             17   \n",
       "18             17   \n",
       "18             17   \n",
       "18             17   \n",
       "18             17   \n",
       "18             17   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        input_sentences  \\\n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                          (Systemic, lupus, erythematosus, (, SLE, ), is, the, prototypical, auto-, immune, connective, tissue, disease, ,, affecting, 5, million, indivi-, duals, worldwide, ,, mainly, women, during, the, fertile, age, [, 1, ], .)   \n",
       "1                                                                                                                                                                                                                                                                            (SLE, is, characterised, by, a, multifactorial, pathogenesis, ,, in, which, the, combination, of, a, favourable, genetics, and, the, inter-, vention, of, external, agents, may, induce, the, chronic, activation, of, the, innate, (, neutrophils, ,, macrophages, ,, complement, system, ), and, the, adaptive, (, T, and, B, lymphocytes, ,, plasma, cells, ,, auto-, antibodies, ), immune, system, .)   \n",
       "1                                                                                                                                                                                                                                                          (Contrary, to, other, autoimmune, diseases, ,, such, as, rheuma-, toid, arthritis, (, RA, ), or, spondyloarthritis, ,, whose, prognosis, has, noteworthy, been, improved, by, the, advent, of, biologic, agents, and, small, molecules, ,, the, treatment, of, SLE, still, relies, on, the, combination, of, traditional, and, symptomatic, drugs, and, usually, shows, less, successful, results, ,, Figure, 2, [, 8, ], .)   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                          (In, this, light, ,, the, formulation, of, human-derived, or, syn-, thetic, peptides, ,, able, to, prevent, specific, steps, of, the, immu-, nologic, cascade, occurring, in, SLE, ,, appears, a, fascinating, alternative, way, to, address, this, complicated, disease, .)   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                          (Thanks, to, genetic, engineering, and, proteomics, ,, it, has, been, possible, to, build, libraries, containing, a, large, collection, of, human, peptides, ,, all, potentially, screenable, for, the, use, in, disease, .)   \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                      (The, aim, of, this, review, is, to, report, the, evidence, concern-, ing, the, rationale, ,, the, efficacy, ,, and, the, safety, of, therapeutic, peptides, developed, or, under, development, for, SLE, ,, and, to, discuss, the, future, place, in, therapy, of, these, innovative, drugs, .)   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                     (Therapeutic, peptides, include, a, class, of, pharmaceutical, com-, pounds, consisting, of, amino, acid, chains, of, various, length, (, usually, less, than, 40, amino, acids, ), [, 21, ], ,, isolated, from, natural, sources, ,, or, artificially, synthesized, [, 24, ], .)   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (Given, the, high, specificity, for, their, target, and, the, low, toxicity, ,, therapeutic, peptides, would, ideally, represent, the, therapy, of, choice, in, SLE, patients, .)   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                          (To, date, ,, no, therapeutic, peptide, has, been, licensed, and, marketed, for, the, use, in, SLE, patients, ,, although, some, of, them, have, entered, the, phase, II, or, III, of, drug, development, .)   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                               (The, next, paragraphs, report, and, discuss, the, current, evidence, concerning, unconjugated, and, conjugated, therapeutic, peptides, under, preclinical, and, clinical, investigation, ,, and, potential, novel, candidates, for, SLE, treatment, .)   \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (Results, and, targets, are, resumed, and, illustrated, in, Table1, ,, Table2, and, Figure, 4, .)   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (SLE, patients, and, animal, models, are, characterized, by, the, production, of, autoantibodies, reacting, against, epitopes, of, the, spliceosome, .)   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                    (Following, these, enthusiastic, preliminary, data, ,, a, number, of, phase, II, and, phase, III, RCTs, tested, the, efficacy, and, safety, profile, of, the, 21-mer, peptide, P140, in, active, SLE, patients, .)   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                (Among, them, ,, the, 57-day, open-label, dose-escalation, early, phase, II, trial, was, conducted, in, a, small, cohort, of, 20, Bulgarian, SLE, patients, and, showed, encouraging, serologic, and, clinical, findings, [, 36, ], .)   \n",
       "3                                                                                                                                                                                                                                                (Two-phase, IIb, studies, with, similar, standard, protocols, were, independently, conducted, in, SLE, patients, randomized, to, receive, 200, mcg, of, the, 21-mer, peptide, P140, conditioned, in, 5.4, %, mannitol, every, 2, or, 4, weeks, or, placebo, ,, and, sponsored, by, Immu-Pharma, and, Teva, Pharmaceutical, Industries, (, Cephalon, ), (, [, 40, ], and, ClinicalTrial.gov, ID, NCT01135459, ,, respec-, tively, ), .)   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (In, two, parallel, phase, IIb, RCTs, ,, the, efficacy, and, safety, profile, of, a, 21-mer, peptide, P140, in, 10, %, trehalose, (, Forigerimod, ,, ImmuPharma, ), was, also, investigated, [, 41, ], .)   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (Controversial, results, instead, characterize, phase, III, investiga-, tions, .)   \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (The, ImmuPharma-sponsored, phase, III, NCT02504645, trial, was, recently, completed, and, results, posted, at, www.clinicaltrials, ., gov, .)   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (Complementarity, determining, regions, (, CDRs, ), encompass, the, variable, portions, of, antibodies, and, TCR, that, recognize, and, interact, with, antigens, .)   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      (The, successful, findings, that, emerged, from, preclinical, research, paved, the, way, for, further, clinical, studies, in, human, disease, .)   \n",
       "4                                                                                                                                                                                                                                                                                                    (The, apparently, conflicting, results, concerning, the, efficacy, of, Edratide, may, be, explained, on, the, ground, of, the, different, scoring, method, (, SLEDAI-2K/AMS, and, BILAG, ), used, for, the, assessment, of, clinical, response, (, with, SLEDAI-2, K, only, captur-, ing, complete, response, and, BILAG, capturing, both, partial, and, complete, response, ), .)   \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                   (According, to, these, considerations, ,, the, efficacy, and, safety, of, Edratide, should, be, reassessed, in, long-term, studies, con-, ducted, in, wider, SLE, cohorts, ,, as, well, as, in, specific, subsets, of, patients, .)   \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                                    (On, the, basis, of, experiments, on, both, animal, and, human, cells, ,, it, has, been, shown, that, heavy, chains, (, HC, ), of, anti-dsDNA, antibodies, can, behave, as, immunogenic, epitopes, and, elicit, a, T, cell, response, [, 64, ], .)   \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ( )   \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (Noteworthy, ,, using, NZBxNZW, F1, mice, ,, Skaggs, et, al., eval-, uated, the, effect, of, the, oral, administration, of, pConsensus, on, clinical, manifestations, and, serum, autoantibody, titers, [, 67, ], .)   \n",
       "6                                                                                                                                                                                                                                                                                                                                  (For, a, long, time, ,, it, was, believed, that, SLE, glomerulonephritis, could, be, the, result, of, immune, complex, deposition, ,, however, ,, recent, evidence, suggests, that, it, may, also, derive, from, the, direct, interaction, of, autoantibodies, with, autoantigens, present, in, the, glomerular, extracellular, matrix, [, 69, ], .)   \n",
       "6                                                                                                                                                                                                                                                                             (Also, ,, another, isolated, study, identified, a, 12, amino, acid, pep-, tide, (, ALW, ), ,, recognized, by, a, panel, of, murine, PL9, -, 11, IgG, anti-, DNA, isotypes, ,, which, was, able, to, prevent, in, vitro, the, binding, of, anti-DNA, antibodies, to, DNA, ,, as, well, as, to, laminin, ,, mesangial, cells, ,, and, isolated, glomeruli, in, both, SLE, mice, and, patients, [, 74, ], .)   \n",
       "6                                                                                                                                                                                                                                                                                                                                                   (Though, still, preliminary, ,, research, on, peptides, structurally, related, to, laminin, may, carve, out, a, niche, for, the, treatment, of, SLE, glomerulonephritis, ,, and, studies, evaluating, the, biological, effect, of, these, medications, on, the, different, glomerular, injury, patterns, should, be, encouraged, .)   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (Nucleosomes, consist, of, chromatin, packages, around, an, octameric, histone, core, .)   \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         (In, SLE, ,, antibodies, reacting, against, components, of, nucleosomes, represent, a, hallmark, of, the, disease, and, their, titers, are, associated, with, disease, activity, [, 75, ], .)   \n",
       "7                                                                                                                                                                                                                                                                                                                                                        (An, interesting, experiment, on, MRL/LPR, mouse, models, showed, that, the, oral, administration, of, the, IIIM1, nonapeptide, ,, derived, from, a, human, and, murine, T, immunodominant, epitope, placed, within, H2A, ,, was, effective, in, treating, both, the, early, and, late, stages, of, the, disease, [, 80, ], .)   \n",
       "7   (To, resume, ,, nucleosomal, peptides, offer, several, attractive, opportunities, :, 1, ), they, do, n’t, elicit, allergic, reactions, and, are, relatively, atoxic, ,, as, already, present, in, the, T, and, B, repertoire, of, recognized, epitopes, ;, 2, ), are, effective, at, very, low, concentra-, tions, (, 1, mcg/kg, in, mice, corresponding, to, 0.2–2, mg/kg, in, humans, ), ;, 3, ), are, highly, soluble, and, easily, absorbed, ;, 4, ), though, rapidly, degraded, ,, they, impart, long-lasting, tolerogenic, signals, in, pDC, ;, 5, ), are, recognized, by, both, MHC, class, I, and, II, molecules, irrespective, of, the, human, leukocyte, antigen, (, ...)   \n",
       "8                                                                                                                                                                                                                                                                                                                                      (It, has, been, demonstrated, that, anti-dsDNA, antibodies, passing, across, the, blood-brain, barrier, (, BBB, ), are, able, to, cross-react, with, the, N-methyl-D-aspartate, receptor, (, NMDAR, ), of, neuronal, cells, ,, inducing, neuron, depolarization, and, apoptosis, in, both, SLE, individuals, and, mouse, models, [, 82,83, ], .)   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       (Glatiramer, acetate, (, Teva, Pharmaceutical, Industries, ), is, a, heterologous, peptide, therapy, approved, for, the, treatment, of, multiple, sclerosis, .)   \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         (It, consists, of, a, pool, of, synthetic, peptides, sharing, the, four, natural, amino, acids, L-glutamic, acid, ,, L-alanine, ,, L-tyrosine, ,, and, L-lysine, [, 87, ], .)   \n",
       "10                                                                                                                                                                                                                                                                                                                                                                      (Thymopentin, (, TP-5, ), is, an, analog, pentapeptide, synthesized, on, the, basis, of, hormones, extracted, from, thymus, gland, ,, and, includes, the, five, amino, acid, residues, 32–36, (, Arg1-Lys2-Asp3-, Val4-Tyr5, ), of, thymopoietin, 2, ,, influencing, the, biological, activity, [, 91,92, ], .)   \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       (AMG623, is, a, peptibody, carrying, four, high-affinity, BLyS-, binding, peptides, grafted, onto, the, Fc, portion, of, a, IgG1, [, 97, ], .)   \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                   (The, compound, was, electively, designed, for, SLE, on, the, basis, of, the, results, of, a, phage, display, library, screening, ,, yielding, a, group, of, peptides, binding, to, both, soluble, and, membrane-, bound, BLyS, with, high, affinity, [, 98, ], .)   \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ( , AMG623, (, blisibimod, ,, Anthera, Pharmaceuticals, ), entered, the, clinical, phase, of, drug, development, and, was, tested, in, a, number, of, phase, II, and, III, RCTs, with, conflicting, results, .)   \n",
       "11                                                                                                                                                                                                                                                                                                                                                         (The, phase, II, PEARL-SC, study, (, ClinicalTrial.gov, ID, NCT01162681, ), aimed, to, assess, the, efficacy, and, safety, of, s.c, ., blisibimod, at, three, different, dose, regimens, (, 100, mg, every, week, ,, 200, mg, every, week, or, 200, mg, every, 4, weeks, ), in, 547, recruited, SLE, patients, [, 101, ], .)   \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (The, efficacy, and, safety, profile, of, blisibimod, was, then, tested, in, three, phase, III, RCTs, .)   \n",
       "12                                                                                                                                                                                                                                                                                                                                                                                     (Contrary, to, other, peptides, ,, whose, pharmacologic, effects, in, SLE, have, been, characterized, in, preclinical, studies, and, RCTs, ,, the, evidence, concerning, the, efficacy, of, AMG531, or, romiplos-, tim, (, Amgen, ), in, SLE, derives, from, real-life, clinical, experience, .)   \n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                           (The, molecule, C-X-C, motif, chemokine, receptor, 4, (, CXCR4, ), is, a, seven-transmembrane, G-protein-coupled, receptor, expressed, on, blood, cells, ,, endothelial, cells, ,, epithelial, cells, ,, fibroblasts, ,, and, cancer, cells, [, 113, ], .)   \n",
       "14                                                                                                                                                                                                                                                                                                                                                               (Due, to, the, impaired, clearance, of, nucleic, acids, ,, the, endoplas-, mic, reticulum, (ER)-resident, protein, stimulator, of, interferon, genes, (STING)-cyclic, GMP-AMP, synthase, (, cGAS, ), pathway, is, typically, hyper-activated, in, SLE, and, associated, to, the, type, I, IFN, response, [, 118, ], .)   \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               (The, administration, of, peptides, designed, on, the, basis, of, spe-, cific, viral, sequences, hyper-expressed, in, SLE, may, induce, immune, tolerance, via, a, booster, effect, .)   \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (The, Torque, teno, virus, (, TTV, ), is, a, human, circular, DNA, virus, transmitted, by, blood, transfusions, .)   \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                   (Additionally, ,, about, one, third, of, SLE, patients, even, without, any, prior, exposure, to, the, human, immunodeficiency, virus, (, HIV, ), ,, produce, antibodies, reacting, against, the, epitopes, of, the, HIVp24core, .)   \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 (HERVs, are, ancient, retroviral, genetic, insertions, accounting, for, 8, %, of, human, genome, ,, whose, reactivation, has, been, asso-, ciated, with, autoimmunity, [, 129, ], .)   \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                    (Bahrami, et, al., tested, with, success, a, peptide, ,, called, Env59-GP3, and, synthesized, on, the, basis, of, the, immunosuppressive, (, ISU, ), domain, of, the, env, protein, of, HERV-H, ,, in, a, mouse, model, of, experimental, autoimmune, encephalomyelitis, (, EAE, ), [, 135, ], .)   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                                     (Human, derived, or, artificially, synthesized, therapeutic, peptides, might, appear, a, safe, and, efficacious, alternative, to, conven-, tional, agents, currently, considered, the, gold-standard, treat-, ment, for, SLE, .)   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                            (For, most, of, these, compounds, research, is, still, ongoing, at, a, preclinical, stage, ,, while, only, two, peptides, (, the, 21-mer, peptide, P140, and, the, CDR1-based, peptide, ), and, a, peptibody, (, blisibimod, ), entered, the, clinical, phase, of, the, investigation, .)   \n",
       "16                                                                                                                                                                                                                                                                                                       (Firstly, ,, any, comparison, between, preclinical, and, clinical, data, is, indeed, very, risky, and, challenging, ,, since, the, two, con-, texts, noteworthy, differ, in, drug, doses, and, routes, of, delivery, ,, disease, phenotype, ,, serology, ,, co-medications, ,, assessment, methods, ,, study, design, ,, time, of, observation, and, statistical, analysis, .)   \n",
       "16                                                                                                                                          (Secondly, ,, the, endpoints, of, preclinical, and, clinical, studies, were, often, unmatchable, ,, as, in, the, first, case, they, focused, on, peripheral, blood, hyper-cellularity, ,, glomerulonephritis, ,, autoan-, tibody, titers, ,, neuronal, damage, ,, perivascular, inflammatory, infiltrates, ,, and, survival, of, SLE, animal, models, ,, whereas, ,, in, the, second, case, ,, they, were, based, on, the, overall, clinical, improvement, ,, measured, through, validated, scoring, systems, at, prefixed, time-points, .)   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      (Thirdly, ,, SLE, patients, represent, a, non-homogeneous, cate-, gory, with, polyhedral, manifestations, reflecting, the, numerous, pathogenic, pathways, being, simultaneously, activated, .)   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           (Post-hoc, analyses, reported, a, better, efficacy, of, clinically, tested, peptides, in, selected, SLE, cohorts, ,, namely, those, patients, having, anti-dsDNA, antibody, positivity, .)   \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    (A, separate, story, ,, instead, ,, lies, below, the, disappointing, results, observed, during, the, clinical, experimentation, of, the, peptibody, blisibimod, [, 101,104, ], .)   \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (Better, knowledge, of, the, pathogenesis, of, SLE, is, expected, to, enrich, the, therapeutic, armamentarium, and, facilitate, the, man-, agement, of, the, disease, .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                    (The, treatment, of, SLE, still, relies, on, a, conservative, approach, ,, combining, multiple, unselective, immunosuppressive, agents, [, 8, ], and, ,, consecutively, ,, increasing, the, risk, of, unwanted, side, effects, .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                     (In, this, effervescent, panorama, ,, therapeutic, peptides, ,, able, to, interfere, with, the, most, crucial, steps, of, SLE, immunopathogen-, esis, ,, may, represent, an, additional, intriguing, pharmacologic, strategy, .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (To, date, ,, no, therapeutic, peptide, has, been, licensed, and, marketed, for, the, use, in, SLE, patients, .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                        (Other, peptides, (, pConsensus, ,, laminin-derived, peptide, ,, nucleosomal, peptides, ,, DWEYS, peptide, ,, glatiramer, acetate, ,, TP-5, ), have, been, tested, in, SLE, preclinical, models, ,, with, promis-, ing, findings, [, 65,73,78,85,89,94, ], .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                        (The, discovery, of, novel, molecular, targets, is, expected, to, enrich, ,, in, the, next, years, ,, the, panorama, of, therapeutic, peptides, for, SLE, ,, among, which, CXCR4, and, STING, antagonists, and, virus-, derived, peptides, seem, promising, candidates, [, 116,119,135, ], .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                 (Meanwhile, ,, research, is, focusing, on, the, optimization, of, the, physicochemical, structure, of, preexisting, peptides, with, the, intention, to, improve, their, pharmacologic, properties, ,, including, bioavailability, and, half-life, .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                           (Peptibodies, ,, consisting, of, fusion, proteins, retaining, a, peptide, sequence, grafted, onto, the, Fc, portion, of, a, Ig, ,, represent, another, fair, example, of, peptide, molecular, engineer-, ing, [, 29, ], .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   (Unconjugated, peptides, might, appear, even, safer, than, con-, jugated, peptides, ,, as, they, undergo, a, rapid, proteolysis, ,, gener-, ating, harmless, simple, amino, acids, [, 40,57, ], .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (Based, on, these, considerations, ,, therapeutic, peptides, would, eventually, offer, several, advantages, in, SLE, treatment, that, may, be, resumed, in, the, following, scenarios, .)   \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                       (A, hypothetical, list, of, specific, therapeutic, indications, of, the, peptides, designed, or, designable, for, SLE, ,, whose, preclinical, and, clinical, evidence, has, been, discussed, in, this, review, ,, is, provided, in, Table3, .)   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     gpt3_output  \n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                Systemic lupus erythematosus (SLE) is a disease that affects 5 million people worldwide, mainly women during the fertile age.\\n  \n",
       "1                             SLE is a disease that is caused by the combination of a genetic predisposition and an environmental trigger.\\nThe genetic predisposition is like a gun, and the environmental trigger is like a bullet.\\nThe combination of the gun and the bullet makes the gun go off.\\nThe gun is like your genes, and the bullet is like something in your environment.\\nThe combination of your genes and something in your environment makes your disease go off.\\nThe disease is like an explosion, and the  \n",
       "1                                                                                                                                                                                                Contrary to other autoimmune diseases, such as rheuma- toid arthritis (RA) or spondyloarthritis, whose prognosis has been improved by the advent of biologic agents and small molecules, the treatment of SLE still relies on the combination of traditional and symptomatic drugs and usually shows less successful results.\\n  \n",
       "1                                                                                                                                                                                                                                                                                                        In this light, the creation of human-derived or synthetic peptides, able to prevent specific steps of the immune cascade occurring in SLE, appears a fascinating alternative way to address this complicated disease.\\n  \n",
       "1                                                                                                                                                                                                                                                                                                                                  Thanks to genetic engineering and proteomics, it has been possible to build libraries containing a large collection of human proteins, all potentially screenable for the use in disease.\\n\\n  \n",
       "1                                                                                                                                                                                                                                                            This review is about a new kind of medicine that can help people with a disease called lupus. This medicine is made from special proteins that help the body fight the disease. The medicine is very safe and effective, but it is not yet approved by the FDA.\\n\\n  \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                             Some drugs are made from amino acids, which are the building blocks of proteins.\\n  \n",
       "2                \"Given the high specificity for their target and the low toxicity, therapeutic peptides would ideally represent the therapy of choice in SLE patients.\"\\n\"\\n\\nThe National Library of Medicine (NLM) has a program called \"Peptide Atlas\" that is designed to help researchers identify peptides that bind to a protein of interest. The Peptide Atlas is a database of experimentally determined peptide-protein binding data. The data are derived from the scientific literature and are manually curated by  \n",
       "2                                                                                                                                                                                                                                                                                                                                                   Until now, no drug made from a protein has been approved for use in people with lupus.\\n\"\"\\n\\nIn the same way, I have rewritten the following passage for my fifth grader:\\n  \n",
       "2                                                                                                                                                                                                                                                                                                                                                                                      The next paragraphs discuss the current evidence about the peptides that doctors are testing to see if they can help people with lupus.\\n  \n",
       "2   \"Results and targets are shown in Table 1, Table 2, and Figure 4.\"\\n\\nThe following is an example of a paragraph written in plain language:\\n\\n\"The purpose of this report is to describe the results of the research conducted on the impact of the new product on the sales of the company. The report is divided into five sections. The first section describes the research methodology used to collect data. The second section presents the results of the analysis. The third section describes the conclusions that  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                           SLE patients and animal models are characterized by the production of autoantibodies reacting against epitopes of the spliceosome.\\n  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                        A number of studies were done to test the effects of a new drug on people with lupus.\\n  \n",
       "3                                                                                                                                                                                                                                                                                                                                       The 57-day open-label dose-escalation early phase II trial was conducted in a small cohort of 20 Bulgarian SLE patients. The trial showed encouraging serologic and clinical findings.\\n  \n",
       "3                                                                                                                      Two studies were done. In one study, people with SLE were given a drug (P140) every two weeks. In the other study, people with SLE were given a drug (P140) every four weeks. In both studies, the drug was given by injection.\\n\\nThe drug was made by Immu-Pharma and Teva Pharmaceutical Industries (Cephalon). The first study was sponsored by Immu-Pharma, and the second study was sponsored by Te  \n",
       "3                                                                                                                                                                                                   In two studies of people with cancer, the drug Forigerimod was given to some patients. The drug is a 21-mer peptide, which means it is made of 21 amino acids. The drug was given to patients in 10% trehalose, which means that 10% of the drug was mixed with 90% of trehalose, a sugar.\\n\"\"\\n                   \\nI'm not  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                         Controversial results instead characterize phase III investigations.\\n  \n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                   A study sponsored by ImmuPharma was recently completed. The results of the study were posted at a website.\\n  \n",
       "4                                                                                                       Antibodies and T-cells are like two puzzle pieces that fit together.\\nComplementarity determining regions (CDRs) are the puzzle pieces that fit together.\\nComplementarity determining regions (CDRs) are the variable parts of the puzzle pieces.\\nAntigens are like the puzzle you want to solve.\\nAntigens are like the puzzle you want to solve.\\nAntigens are like the puzzle you want to solve.\\nAntigens are like  \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                    \"Scientists did experiments on animals to learn how to help sick people.\"\\n  \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                 The different results about the medicine can be explained because the test used to see if the medicine worked was different.\\n  \n",
       "4                                                                                                                                                                                                                                                                                                                                                                                              According to these considerations, the drug Edratide should be tested in long-term studies in a wider group of people with SLE.\\n  \n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                    It has been shown that the heavy chains of anti-dsDNA antibodies can cause the body to make T cells that attack the body.\\n  \n",
       "5                                                                                                                                                     \\nI'm not sure if this is the right answer or not, but it's what I got from the passage.\\n\\nMy son was very happy with my answer. I was happy to help him.\\n\\nI'm not sure if this is the right answer or not, but it's what I got from the passage.\\n\\nMy son was very happy with my answer. I was happy to help him.\\n\\nI'm not sure if this is the right answer or not,  \n",
       "5                                                                   A group of scientists used a special kind of mouse to see if a drug could help people with a disease. The disease was rheumatoid arthritis. The drug was called pConsensus.\\nThe scientists gave the drug to the mice and then looked at how the mice acted and how their bodies changed.\\nThe scientists found that the drug helped the mice.\\nThe scientists also found that the drug helped people with rheumatoid arthritis.\\n\"\"\\n\\nThe original text:\\n  \n",
       "6                                                                                            It was believed that SLE could be the result of immune complex deposition, but recent evidence suggests that it may also derive from the direct interaction of autoantibodies with autoantigens present in the glomerular extracellular matrix.\\n\"\"\\n   \\nHe said, \"Oh, I get it!\"\\n   \\nI think that the medical literature is written in a way that is very hard for the average person to understand. I think it is written in a  \n",
       "6                                   A medicine was made that prevents the body from attacking itself.\\n\"\" \\n\\nIn the early 1980s, the National Institutes of Health (NIH) funded a study of the effectiveness of homeopathic treatment of hay fever. The study was conducted by Dr. Robert E. McCarron, Jr., a homeopathic physician and researcher at the University of California, Irvine. The study involved 40 patients with hay fever who were randomly assigned to receive either a homeopathic medicine or a placebo. The  \n",
       "6                                                                                                                                                                                                                                                                Although still early, research on peptides structurally related to laminin may be useful for treating SLE glomerulonephritis. Studies evaluating the biological effect of these medications on the different glomerular injury patterns should be encouraged.\\n  \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 The octamer is the core of the nucleosome.\\n\\n  \n",
       "7                                                                                                                                                                                                                                                                                                                                                                                In SLE, antibodies that react against the things that make up the little beads on the ends of the DNA strands are a sign of disease activity.\\n  \n",
       "7                                                                                              A scientist did an experiment on mice with a disease. He gave them a pill that made them better.\\n\\n\"The Scientist\" is the name of a book by James Watson, who was the co-discoverer of DNA. It is a biography for young adults.\\n\\nThe book is written in the first person, as if Watson is telling his own story. It begins with his childhood and ends with his Nobel Prize. It includes the story of how he met his wife, and  \n",
       "7                                                                                                                               1) Nucleosomal peptides are small pieces of DNA and RNA.\\n2) They don't cause allergic reactions.\\n3) They are effective at very low concentrations.\\n4) They are easily absorbed.\\n5) They last a long time in your body.\\n6) They work with any HLA haplotype.\\n7) They help the immune system to be less harmful to the body.\\n8) They are effective at early and late stages of the disease.  \n",
       "8                                                                                                                                                                                                                                                                                                                                                                                                                  It has been shown that the antibodies that attack your brain cells can also attack the brain cells of mice.\\n  \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Glatiramer acetate is a drug that treats multiple sclerosis.\\n  \n",
       "9                                                                                                                                                                                                                                                                                                                                                                                   It is a pool of synthetic peptides that are made up of the four natural amino acids, L-glutamic acid, L-alanine, L-tyrosine, and L-lysine.\\n  \n",
       "10                                                                                                                                      TP-5 is a synthetic version of a hormone found in the thymus gland. It is made up of 5 amino acids, and it affects the body's ability to make white blood cells.\\nTP-5 is used to treat people who have a low white blood cell count.\\nTP-5 is also used to treat people who have a low red blood cell count.\\nTP-5 is also used to treat people who have a low platelet count.\\nTP-5 is  \n",
       "11                                                                                                                              AMG623 is a drug that is made to attack a cancer cell. It is made by taking a part of the body's immune system (the Fc part of the body's antibodies) and adding four parts of a cancer cell (the BLyS-binding peptides).\\nAMG623 is a drug that is made to attack a cancer cell. It is made by taking a part of the body's immune system (the Fc part of the body's antibodies) and adding four  \n",
       "11                                                                                                                                      The researchers made a new drug to treat lupus, based on a library of chemicals they made in the lab.\\n\"\"\\n    I told him that the rest of the passage is a list of chemicals and their names, and that he should skip it.\\n\"\"\\n    I told him that the rest of the passage is a list of chemicals and their names, and that he should skip it.\\n\"\"\\n    I told him that the rest of the  \n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                       A drug called blisibimod was tested in many trials. The trials had different results.\\n  \n",
       "11                                                                                                 A study was done on 547 people with SLE. They were given a drug called blisibimod (which is a type of medicine called a biologic). The study was to see if the drug worked and if it was safe. The study was divided into three groups, each group got a different dose of the drug. The first group got 100 mg of the drug every week, the second group got 200 mg of the drug every week, and the third group got 200 mg of  \n",
       "11                                                                                                                                                                                                                                                                                                                                              A new drug called blisibimod was tested in three different studies.\\n\"\"\\n\\nIn the same vein, the following passage was translated from a scientific paper into plain language:\\n  \n",
       "12                                                                                                                 Contrary to other drugs, whose effects in SLE have been studied in the lab and in clinical trials, the effects of AMG531 or romiplostim (Amgen) have only been studied in real life, not in the lab or in clinical trials.\\n\"\"\\n\\nThe FDA approved romiplostim (Nplate) for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids and immun  \n",
       "13                                                                                                               CXCR4 is a protein that is found on the surface of blood cells, endothelial cells, and cancer cells.\\nCXCR4 is a receptor, which means that it can recognize certain chemicals.\\nCXCR4 is a G-protein-coupled receptor, which means that it can recognize certain chemicals by using a special type of protein called a G-protein.\\nCXCR4 is found on the surface of blood cells, endothelial cells, and cancer  \n",
       "14                                                                                                                                                                                                                                                        Due to the impaired clearance of nucleic acids, the endoplas- mic reticulum (ER)-resident protein stimulator of interferon genes (STING)-cyclic GMP-AMP synthase (cGAS) pathway is typically hyper-activated in SLE and associated to the type I IFN response [118].\\n  \n",
       "15                                                                                                                                                                                                                                                                                                                                          If you give a person a shot of a substance that is similar to something that makes them sick, their body will be tricked into thinking it's sick and will stop making the disease.\\n  \n",
       "15                                                                                                                                                                                                                                                                                                                                                                          The Torque teno virus (TTV) is a human circular DNA virus transmitted by blood transfusions.\\nThe virus is transmitted through blood transfusions.\\n  \n",
       "15                                                           About one third of people with SLE produce antibodies against HIV.\\n\"\"\\n\\nIn the late 1980s, a team of researchers led by Dr. William Robinson at the University of Pittsburgh School of Medicine, discovered that a specific subset of B cells in SLE patients are autoreactive and produce antibodies against nuclear antigens. This subset of B cells was named \"nuclear antigens\" B cells (NAB). The NAB were found to be associated with anti-dsDNA antibodies  \n",
       "15                                                                                                                                                                                                                                                                                                                                                                                             HERVs are ancient viruses that have been in our DNA for a long time. Sometimes they can become active again and cause problems.\\n  \n",
       "15                                                                                                       A scientist named Bahrami tested a new drug on mice. The drug was made from a part of a virus called HERV-H. The drug was made from a part of the virus that makes the mouse's immune system stop working. The drug worked, and the mice got better.\\n\\nThe scientist named Bahrami tested the drug on mice with a disease called EAE. EAE is like MS, but it happens in mice. The drug worked, and the mice got better  \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                Human-made drugs might be safer and more effective than the drugs we use now to treat lupus.\\n  \n",
       "16                                                                                                                                                                                                                   For most of these compounds research is still ongoing at a preclinical stage, while only two peptides (the 21-mer peptide P140 and the CDR1-based peptide) and a peptibody (blisibimod) entered the clinical phase of the investigation.\\n\\nI have a PhD in chemistry and I have no idea what this means:\\n  \n",
       "16                                                                                                                                                                                                                                                                                                                                                                            \"It is very hard to compare data from animal studies with data from human studies, because the two types of studies are done in different ways.\"\\n  \n",
       "16                                                                            The endpoints of the first group of studies were different from the endpoints of the second group of studies.\\n\"\"\\nI think that's a fair paraphrase. I'm not sure how to phrase it in a way that is not misleading.\\nI also think it's misleading to say that the endpoints of the first group of studies were \"unmatchable\" with the endpoints of the second group of studies. I think it would be more accurate to say that they were \"different  \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                          Thirdly, SLE patients are a group of people with many different types of problems.\\n  \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                               Doctors found that patients who had anti-dsDNA antibodies did better when they took the drug.\\n  \n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                                              The scientists were disappointed when their experiment failed.\\n  \n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                    Better knowledge of the causes of SLE will help doctors treat it better.\\n  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                              Doctors used to treat SLE with a lot of different medicines, but now they use fewer medicines.\\n  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                    In this exciting new field of medicine, there are drugs that can help people with lupus.\\n  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  No medicine has been invented to cure SLE.\\n  \n",
       "18                                                                                                                                                 Other peptides (pConsensus, laminin-derived peptide, nucleosomal peptides, DWEYS peptide, glatiramer acetate, TP-5) have been tested in SLE preclinical models, with promising findings.\\n\"\"\\n\\nThe following is a list of the peptides that have been tested in SLE preclinical models:\\npConsensus (a consensus sequence of the human protein p53)\\nlaminin-derived peptide  \n",
       "18                                                                                                                                                                                                                                                                                                     The discovery of new drugs that target molecules in the body is expected to improve the treatment of lupus in the next few years. Some of these drugs target molecules called CXCR4 and STING, and some target viruses.\\n  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                               Scientists are trying to make new drugs that are like the ones we already have, but better.\\n\\n  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                            A peptibody is a protein that has a peptide sequence grafted onto the Fc portion of an antibody.\\n  \n",
       "18                                                                                                                                                                                                                                                                                                                                                              Unconjugated peptides might appear even safer than conjugated peptides, as they undergo a rapid proteolysis, generat- ing harmless simple amino acids [40,57].\\n  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                     Based on these considerations, it is possible that some day, a new treatment for SLE will be developed.\\n  \n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                              A list of specific diseases that the peptides designed or designable for SLE can treat is provided in Table 3.\\n  "
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.set_option('display.max_colwidth', None)\n",
    "pd.set_option('display.max_rows', None)\n",
    "\n",
    "df_sections_sents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6887edb5",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "bioasq-biobert2019py3.6",
   "language": "python",
   "name": "bioasq-biobert2019py3.6"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
